

## Listing and evaluation of the results

1: Dr. med.Max Mustermann  
Laboratory Mustermann

Survey of 21 October 2020

Adviser:

617

### Haematology 14 - Immunophenotyping 03 (T, B and NK cells in cellular products)

Analyte	Sample	Unit	Your value	Target value	TV-Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
T-cells	61	/μl	2363	2203	SV	1674	2732	7.3%	0,994	+	
	62		1546	1428	SV	1085	1771	8.3%	1,08	+	
Leucocytes (dual platform)	61	/μl	7420	7252	SV	5512	8992	2.3%	0,318	+	
	62		3640	3598	SV	2734	4462	1.2%	0,19	+	
Proportion T-cells to lymphocytes	61	%	85.9	84.4	SV	64.1	105	1.8%	0,949	+	
	62		85.6	83.6	SV	63.5	104	2.4%	1,09	+	
B-cells	61	/μl	199	247	SV	188	306	-19.4%	-1,03	+	
	62		142	176	SV	134	218	-19.3%	-1,09	+	
Proportion B-cells to lymphocytes	61	%	7.20	9.57	SV	7.27	11.9	-24.8%	-1,94	-	
	62		7.80	10.3	SV	7.83	12.8	-24.3%	-1,39	-	
NK-cells	61	/μl	156	134	SV	102	166	16.4%	0,843	+	
	62		100	89.1	SV	67.7	110	12.2%	0,542	+	
Proportion NK-cells to lymphocytes	61	%	5.70	5.11	SV	3.88	6.34	11.5%	0,786	+	
	62		5.50	5.16	SV	3.92	6.40	6.6%	0,422	+	

Analyte	Sample	Your unit	Stated value	Conversion factor	Method	Manufacturer	Device	Gating strategy	platform	viability
T-cells	61		2363	1.00		CU	CU41		224	2
	62		1546	1.00						
Leucocytes (dual platform)	61		7420	1.00		CU	CU41			
	62		3640	1.00						
Proportion T-cells to lymphocytes	61		85.9	1.00		CU	CU41			
	62		85.6	1.00						
B-cells	61		199	1.00		CU	CU41		224	2
	62		142	1.00						
Proportion B-cells to lymphocytes	61		7.20	1.00		CU	CU41			
	62		7.80	1.00						
NK-cells	61		156	1.00		CU	CU41		224	2
	62		100	1.00						
Proportion NK-cells to lymphocytes	61		5.70	1.00		CU	CU41			
	62		5.50	1.00						



## Individual summary of results

1: Dr. med.Max Mustermann  
Laboratory Mustermann

Survey of 21 October 2020



617

### Haematology 14 - Immunophenotyping 03 (T, B and NK cells in cellular products)

#### Leucocytes (dual platform) (/μl, N = 18)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
others	61	7252	5512 - 8992	7252	7.29	18	88.9	88.9
	62	3598	2734 - 4462	3598	6.14	18	88.9	



Rate of success: 88,9%



#### Proportion T-cells to lymphocytes (% , N = 36)

Collective	Sample	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all	61	84.4	64.1 - 105	84.4	1.87	36	100	100
	62	83.6	63.5 - 104	83.6	2.20	36	100	

Rate of success: 100%







## Proportion B-cells to lymphocytes (% , N = 29)

Collective	Sam-ple	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all	61	9.57	7.27 - 11.9	9.57	12.7	29	89.7	79.3
	62	10.3	7.83 - 12.8	10.3	17.5	29	82.8	



Rate of success: 79,3%



## Proportion NK-cells to lymphocytes (% , N = 26)

Collective	Sam-ple	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all	61	5.11	3.88 - 6.34	5.11	14.7	26	96.2	84.6
	62	5.16	3.92 - 6.40	5.16	15.6	26	88.5	



Rate of success: 84,6%



## T-cells (/µl, N = 51)

Collective	Sam-ple	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all	61	2203	1674 - 2732	2203	7.31	51	96.1	96.1
	62	1428	1085 - 1771	1428	7.63	51	98.0	


Rate of success: 96,1%





B-cells (/μl, N = 39)										
Collective	Sam-ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	61	247	188	-	306	247	18.8	39	82.1	71.8
	62	176	134	-	218	176	17.7	39	79.5	

Rate of success: 71,8%



NK-cells (/μl, N = 32)										
Collective	Sam-ple	Target value	Target range			Participants collective			Rate (%)	
						AVG	CV	Num.	Sam.	total
all	61	134	102	-	166	134	19.5	32	78.1	65.6
	62	89.1	67.7	-	110	89.1	22.6	32	68.8	

Rate of success: 65,6%

